Online Database of Chemicals from Around the World

1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
[CAS# 1801787-56-3]

List of Suppliers
Taizhou Crene Biotechnology Co., Ltd. China Inquire  
+86 (576) 8881-3233
8820-5808
+86 13396860566
order@pharm-intermediates.com
QQ chat
Chemical manufacturer since 2011
chemBlink standard supplier since 2009
BOC Sciences USA Inquire  
+1 (631) 485-4226
info@bocsci.com
Chemical manufacturer
chemBlink standard supplier since 2010
Complete supplier list of 1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
Identification
Classification API >> Other chemicals
Name 1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
Synonyms OICR 9429
Molecular Structure CAS # 1801787-56-3, 1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide, OICR 9429
Molecular Formula C29H32F3N5O3
Molecular Weight 555.59
CAS Registry Number 1801787-56-3
SMILES CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=CC(=C3)CN4CCOCC4)NC(=O)C5=CNC(=O)C=C5C(F)(F)F
Properties
Solubility Very slightly soluble (0.12 g/L) (25 ºC), Calc.*
Density 1.325±0.06 g/cm3 (20 ºC 760 Torr), Calc.*
* Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2016 ACD/Labs)
Safety Data
Hazard Symbols symbol   GHS07 Warning    Details
Hazard Statements H315    Details
Precautionary Statements P280    Details
SDS Available
up Discovory and Applicatios
1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl ]-6-Oxo-4-(trifluoromethyl)-3-pyridinecarboxamide, commonly known as DTMP, is a synthetic compound developed through medicinal chemistry research.

DTMP has pharmacological activity as a potent and selective inhibitor of specific biological targets in the human body. These targets may include enzymes, receptors, or proteins involved in disease pathways or cellular processes. DTMP has potential applications in the development of drugs for the treatment of various diseases. DTMPs can be optimized and refined through structure-activity relationship (SAR) studies to enhance their pharmacokinetic properties and therapeutic efficacy. DTMP may exhibit neuropharmacological effects due to interactions with neurotransmitter receptors or modulators in the central nervous system (CNS). This has important implications for the treatment of neurological disorders such as epilepsy, neuropathic pain or psychiatric disorders. DTMP and related compounds may have anticancer properties and potential use as chemotherapeutic agents. The molecular structure and pharmacological activity of DTMP allow its use in biochemical assays, cell-based assays, or animal models to elucidate the function of specific biological targets or pathways and to evaluate the effects of potential therapeutic interventions. DTMP and its derivatives hold promise as potential therapeutics for the treatment of diseases and conditions requiring modulation of specific biological targets. This may include neurological disorders, psychiatric disorders, cancer, inflammatory diseases, metabolic disorders or infectious diseases.
Market Analysis Reports
List of Reports Available for 1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
Related Products
2,4-Dihydro-5-(4-methylphenyl)-3H-pyrazol-3-one  (3R,7aS)-2,3-Dihydro-7a-methyl-3-phenylpyrrolo[2,1-b]oxazol-5(7aH)-one  3,4-Dihydro-5-[[(4-methylphenyl)sulfonyl]oxy]-1(2H)-pyridinecarboxylic acid 1,1-dimethylethyl ester  2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one  4,5-Dihydro-1-methyl-1H-phosphole-2-carboxylic acid 1-oxide  2,5-Dihydro-1-methyl-1H-phosphole 1-oxide  (3Z)-2,3-Dihydro-3-[[[4-[methyl(1-piperazinylacetyl)amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester  (3Z)-2,3-Dihydro-3-[[[4-[[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester  [1,3-Dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]methanone  [1,3-Dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]methanone hydrochloride  (3Z)-1,3-Dihydro-4-(4-methyl-1-piperazinyl)-3-(2-oxopropylidene)-2H-1,5-benzodiazepin-2-one  2,3-Dihydro-3-[(4-methyl-1-piperazinyl)phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester  7',8'-Dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one  7',8'-Dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]-spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one hydrochloride (1:2)  N-[(1S)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluorobenzeneacetamide  (2R,3S)-N1-[(3S)-2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide  2-[(1,5-Dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)ethylidene]-2,3-dihydro-1,3,3-trimethyl-1H-indole-5-carboxylic acid methyl ester  1,6-Dihydro-2-methyl-6-oxo-1-phenyl-3-pyridinecarboxylic acid ethyl ester  3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonic acid  3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonic acid ethyl ester